程序性死亡受体-1抑制剂致继发性肾上腺皮质功能减退2例及文献分析  

Two case reports of programmed death receptor-1 inhibitor-induced secondary hypoadrenocorticism and literature analysis

作　　者：潘浩宇 张炯[2] 刘志春[2] 赵亮[2] 王定新 Haoyu PAN;Jiong ZHANG;Zhichun LIU;Liang ZHAO;Dingxin WANG(The First Clinical Medical College of Gansu University of Chinese Medicine,Lanzhou 730000,China;Department of General Surgery,The First People's Hospital of Tianshui,Gansu Tianshui 741000,China;Tianshui Municipal Health Commission,Gansu Tianshui 741000,China)

机构地区：[1]甘肃中医药大学第一临床医学院,兰州730000 [2]天水市第一人民医院普通外科,甘肃天水741000 [3]天水市卫生健康委员会,甘肃天水741000

出　　处：《临床药物治疗杂志》2024年第10期83-86,共4页Clinical Medication Journal

基　　金：甘肃省天水市科技项目(2023-SHFZKJK-3564)。

摘　　要：本文报道2例胃癌术后患者在应用程序性死亡受体-1(PD-1)抑制剂治疗过程中引发肾上腺皮质功能减退,并结合文献资料对2例继发性肾上腺皮质功能减退的发生和治疗过程进行梳理,以期为医师和药师对PD-1抑制剂引起肾上腺皮质功能减退症的鉴别、诊断、治疗提供参考。This article presents two case reports of secondary hypoadrenocorticism following treatment with programmed death receptor-1(PD-1)inhibitors in postoperative gastric cancer patients.We have integrated literature data to analyze the development and management of secondary hypoadrenocorticism in these patients,with the goal of providing a reference for physicians and pharmacists in the identification,diagnosis,and management of hypoadrenocorticism associated with PD-1 inhibitor therapy.

关 键 词：程序性死亡受体-1抑制剂 继发性肾上腺皮质功能减退 不良反应 

分 类 号：R979.19[医药卫生—药品]